Skip to main content
. 2016 Mar 14;126(4):1495–1511. doi: 10.1172/JCI80046

Figure 1. IGF2BP3 is overexpressed in MLL-translocated B-ALL.

Figure 1

(A) Heatmap from the microarray data showing differentially expressed RBPs between B-ALL. IGF2BP3 is highly expressed in MLL-rearranged B-ALL. (B and C) qPCR-based confirmation of overexpression of IGF2BP3 (B) and its previously defined target, CD44 (C), in MLL-rearranged B-ALL (total n = 134; one-way ANOVA followed by Bonferroni’s multiple comparisons test; **P < 0.01, ***P < 0.001, ****P < 0.0001). (D–F) Treatment of RS4;11 cell line with increasing doses of I-BET151. (D) qPCR of MYC, CDK6, and IGF2BP3 levels in RS4;11 cells shows a significant decrease in all 3 mRNA levels (t test MYC, P = 0.04, P = 0.06; IGF2BP3, P < 0.0001, P = 0.1; CDK6, P = 0.005, P = 0.004; 1 μM and 2 μM, respectively). (E and F) Cell cycle analysis by propidium iodide staining after I-BET151 treatment of RS4;11 cells shows G1 arrest secondary to CDK6 inhibition. Experiments were conducted 3× for validation. qPCR assays were normalized to actin (B and C) and RNA Pol II (D). Data represent mean ±SD. See also Supplemental Figure 1.